[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"iron\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:iron":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,52,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100642134","phase-4-ironcare-iron-treatment-in-older-patients-with-hip-fractures-100642134",false,"NCT07659184","IRONCARE: Iron Treatment in Older Patients With Hip Fractures","IRONCARE: Iron Treatment in Older Patients With Hip Fractures - A Double-blinded Placebo-controlled Randomized Trial","Inclusion Criteria:\n\n* Hip fracture (ICD-10 codes: DS720, DS721 and DS722)\n* Low energy trauma\n* Age ≥ 75 years\n* Hemoglobin ≤7.0 mmol\u002FL (11 g\u002FdL) during hospital admission\n\nExclusion Criteria:\n\n* Pathological fracture\n* Periprosthetic fracture\n* Inability to understand or speak Danish\n* Dysphagia and thus inability to swallow study medication\n* Signs of iron overload, hemochromatosis, or hemosiderosis\n* Liver disease (cirrhosis or hepatitis) and transaminase levels \\>3 times upper limit of normal\n* Known allergy to iron formulations\n* Severe asthma\n* Severe hypophosphatemia: \\\u003C0.35 mmol\u002FL\n* Patients already receiving iron supplementation that cannot be paused for the study period\n* Cognitive impairment that results in either memantine-treatment or a Short Portable Mental Status Questionnaire (SPMSQ) score \\> 4","ALL","75 Years",{"count":19,"type":20},528,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The aim of this study is to investigate the effects of intravenous (IV) iron therapy compared to alternate-day oral iron treatment and no supplementation in older patients with hip fractures. This study will examine the impact of iron treatment on fatigue, functional decline, fear of falling, cognitive impairment, and quality of life, as well as its effects on iron stores and hemoglobin levels, with the overall goal of improving postoperative rehabilitation.\n\nThe trial will be conducted on five different hospitals in the Central Region of Denmark (Region Midtjylland).",[26,27,28,29],"Hip Fracture","Anemia","Iron","Placebo - Control",[31,27,32,33,34,35,36,37,38],"Hip fracture","iron","Intravenous iron","mobility","fatigue","hemoglobin","RCT","Placebo","NOT_YET_RECRUITING","2026-06-19",{"date":42,"type":43},"2026-06-24","ACTUAL",{"date":45,"type":20},"2026-10-01",{"date":47,"type":20},"2028-09-30",{"name":49,"class":50},"University of Aarhus","OTHER",5,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":16,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100620915","a-study-on-the-correlation-between-tear-iron-levels-and-the-severity-of-dry-eye-disease-100620915","NCT07363824","A Study on the Correlation Between Tear Iron Levels and the Severity of Dry Eye Disease.","Inclusion Criteria:\n\n* Aged between 18 and 70 years, inclusive.\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* History or clinical suspicion of significant systemic conditions: hematologic diseases, severe systemic infections, malignancies (treated or untreated), or chronic hepatic\u002Frenal insufficiency.\n* Use of artificial tears or any topical eye drops within 2 hours prior to examination.\n* Active ocular allergy, infection, or severe blepharitis within the past 1 month.\n* Systemic or topical use of antibiotics, corticosteroids, NSAIDs, or immunosuppressants within the past 1 month.\n* History of contact lens wear within the past 1 month.\n* History of blood transfusion, ocular surgery, or significant ocular trauma within the past 6 months.\n* Women who are pregnant, breastfeeding, or postmenopausal women undergoing hormone replacement therapy.\n* Known hypersensitivity to fluorescein sodium.",true,"18 Years","70 Years",{"count":62,"type":20},52,"OBSERVATIONAL","This study aims to see if the amount of iron in tears is linked to how severe dry eye disease is. We hope this can lead to a new way to help diagnose and understand dry eye. This is an observational study. We will compare tear samples from people with dry eye to samples from people with healthy eyes. We will measure the iron content in the tears and see if it correlates with standard dry eye test results and symptom scores.",[66,28],"Dry Eye Disease",[68,32],"DED","RECRUITING","2026-02-06",{"date":72,"type":43},"2026-02-10",{"date":70,"type":43},{"date":75,"type":20},"2029-05",{"name":77,"class":50},"Shanghai Changzheng Hospital",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":87,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":90,"conditions":91,"keywords":95,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":78},"100599368","impact-of-iv-iron-on-bleeding-symptoms-in-iron-deficient-patients-with-inherited-bleeding-disorders-100599368","NCT07083583","Impact of IV Iron on Bleeding Symptoms in Iron Deficient Patients With Inherited Bleeding Disorders","Impact of IV Iron on Bleeding Symptoms in Iron Deficient Patients With Inherited Bleeding Disorders: a Single-arm Prospective Observational Study","IRON-BD","Inclusion Criteria:\n\n1. Males and Females \\> 15 years of age\n2. Diagnosed with an Inherited Bleeding Disorder (Von Willebrand disease, platelet disorders, factor deficiencies, or bleeding disorder of unknown cause)\n3. Evidence of Iron Deficiency (Ferritin \\\u003C 50 ng\u002FmL)\n4. Receiving IV iron at Hemophilia Center of Western Pennsylvania\n5. Willingness to have blood drawn\n6. Willing to return to clinic 3 months post infusion for final blood draw, bleeding and quality of life assessments.\n\nExclusion Criteria:\n\n1. Previous thrombosis, VTE History.\n2. Platelet count \\\u003C 100,000 \\* 109\u002FL\n3. Concomitant use of antiplatelet drugs, anticoagulants, aspirin, NSAIDs.","15 Years",{"count":89,"type":20},40,"This is a prospective, single-arm, single-center observational study evaluating the impact of intravenous (IV) iron replacement in patients with inherited bleeding disorders and iron deficiency (ferritin \\\u003C50ng\u002FdL). Subjects will undergo baseline bleeding assessments, quality-of-life measures, and laboratory tests before receiving standard-of-care IV iron. Follow-up blood work and questionnaires will be conducted post-replacement to assess for changes",[92,28,93,94],"Bleeding Disorders","Platelet","Bleeding",[96,97,98],"Iron deficiency","bleeding disorder","platelet function","2025-10-01",{"date":101,"type":43},"2025-10-03",{"date":103,"type":43},"2025-08-08",{"date":105,"type":20},"2027-10-01",{"name":107,"class":50},"Nicoletta C Machin"]